Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Accounts Payables: 2020-2024

Historic Accounts Payables for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $1.6 million.

  • Tango Therapeutics' Accounts Payables fell 45.79% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 45.79%. This contributed to the annual value of $1.6 million for FY2024, which is 42.51% down from last year.
  • Per Tango Therapeutics' latest filing, its Accounts Payables stood at $1.6 million for FY2024, which was down 42.51% from $2.8 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Accounts Payables ranged from a high of $4.5 million in FY2022 and a low of $1.6 million during FY2024.
  • In the last 3 years, Tango Therapeutics' Accounts Payables had a median value of $2.8 million in 2023 and averaged $2.9 million.
  • As far as peak fluctuations go, Tango Therapeutics' Accounts Payables skyrocketed by 75.23% in 2021, and later plummeted by 42.51% in 2024.
  • Tango Therapeutics' Accounts Payables (Yearly) stood at $1.8 million in 2020, then soared by 75.23% to $3.2 million in 2021, then skyrocketed by 38.03% to $4.5 million in 2022, then crashed by 37.46% to $2.8 million in 2023, then tumbled by 42.51% to $1.6 million in 2024.